Journals / Diagnostic and Interventional Radiology / 2018 / Cilt: 24 - Sayı: 1

A comparison between 915 MHz and 2450 MHz microwave ablation systems for the treatment of small diameter lung metastases

Pages
31–37
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION HF ablations resulted in larger ablation margins with fewer local progression compared with LF ablations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE We aimed to retrospectively compare the local tumor control rates between low frequency (LF) and high frequency (HF) microwave ablation devices in the treatment of <3 cm lung metastases.
📊
Key Findings & Data:METHODS A total of 36 patients (55 tumors) were treated with the LF system (915 MHz) and 30 patients (39 tumors) were treated with the HF system (2450 MHz) between January 2011 and March 2016.
💡
Conclusion & Impact:CONCLUSION HF ablations resulted in larger ablation margins with fewer local progression compared with LF ablations.
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

PURPOSE We aimed to retrospectively compare the local tumor control rates between low frequency (LF) and high frequency (HF) microwave ablation devices in the treatment of <3 cm lung metastases. METHODS A total of 36 patients (55 tumors) were treated with the LF system (915 MHz) and 30 patients (39 tumors) were treated with the HF system (2450 MHz) between January 2011 and March 2016. Computed tomography (CT) scans performed prior to and 24 hours after the ablation were used to measure the size of the ablation zone and to calculate the ablation margin. The subsequent CTs were used to detect local tumor progression. Possible predictive factors for local progression were analyzed. All patients had a minimum follow-up of 3 months with a median of 13.8 months for the LF group and 11.7 months for the HF group. RESULTS The ablation margin (P = 0.015), blood vessel proximity (P = 0.006), and colorectal origin (P = 0.029) were significantly associated with the local progression rate. The local progression rates were 36.3% for LF ablations and 12.8% for HF ablations. The 6, 12, and 18 months local progression-free survival rates were 79%, 65.2% and 53% for the LF group and 97.1%, 93.7%, and 58.4% for the HF group, with a significant difference between the survival curves (P = 0.048). CONCLUSION HF ablations resulted in larger ablation margins with fewer local progression compared with LF ablations.

🔖

Cite This Article

S.VOGL, T., ROMAN, A., A.NOUR-ELDİN, N., HOHENFORST-SCHMİDT, W., BEDNAROVA, I., KALTENBACH, B. (2018). A comparison between 915 MHz and 2450 MHz microwave ablation systems for the treatment of small diameter lung metastases. Diagnostic and Interventional Radiology, Cilt: 24 - Sayı: 1, 31–37. https://ajindex.com/articles/350121

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget 2015
  2. 8491–8524. [CrossRef] 2.Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016
  3. 1386–1422. [CrossRef] 3.Wolf FJ, Grand DJ, Machan JT, DiPetrillo TA, Mayo-Smith WW, Dupuy DE. Microwave ab- lation of lung malignancies: effectiveness, CT findings, and safety in 50 patients. Radiology 2008
  4. 871–879. [CrossRef] 4.Vogl TJ, Naguib NN, Gruber-Rouh T, Koitka K, Leh- nert T, Nour-Eldin NE. Microwave ablation therapy: clinical utility in treatment of pulmonary metasta- ses. Radiology 2011
  5. 643–651. [CrossRef] 5.Egashira Y, Singh S, Bandula S, Illing R. Percu- taneous high-energy microwave ablation for the treatment of pulmonary tumors: a retro- spective single-center experience. J Vasc Interv Radiol 2016
  6. 474–479. [CrossRef] 6.Lubner MG, Brace CL, Hinshaw JL, Lee FT, Jr. Mi- crowave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol 2010
  7. S192–203. [CrossRef] 7.Ward RC, Healey TT, Dupuy DE. Microwave abla- tion devices for interventional oncology. Expert Rev Med Devices 2013
  8. 225–238. [CrossRef] 8.Hoffmann R, Rempp H, Erhard L, et al. Com- parison of four microwave ablation devices: an experimental study in ex vivo bovine liver. Radiology 2013
  9. 89–97. [CrossRef] 9.Carrafiello G, Mangini M, Fontana F, et al. Microwave ablation of lung tumours: sin- gle-centre preliminary experience. Radiol Med 2014
  10. 75–82. [CrossRef] 10.Vogl TJ, Worst TS, Naguib NN, Ackermann H, Gruber-Rouh T, Nour-Eldin NE. Factors influenc- ing local tumor control in patients with neoplas- tic pulmonary nodules treated with microwave ablation: a risk-factor analysis. AJR Am J Roent- genol 2013
  11. 665–672. [CrossRef] 11. Ierardi AM, Mangano A, Floridi C, et al. A new system of microwave ablation at 2450 MHz: preliminary experience. Updates Surg 2015
  12. 39–45. [CrossRef] 12. Alonzo M, Bos A, Bennett S, Ferral H. The emprint ablation system with thermosphere technology: one of the newer next-generation microwave ablation technologies. Semin Intervent Radiol 2015
  13. 335–338. [CrossRef] 13. Sun Y, Cheng Z, Dong L, Zhang G, Wang Y, Liang P. Comparison of temperature curve and ablation zone between 915- and 2450-MHz cooled-shaft microwave antenna: results in ex vivo porcine livers. Eur J Radiol 2012
  14. 553–557. [CrossRef] 14. Sun Y, Wang Y, Ni X, et al. Comp